The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1499
July 18, 2016
View Complete Issue         Table of Contents 2019 
Onzetra Xsail - Sumatriptan Nasal Powder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Onzetra Xsail - Sumatriptan Nasal Powder
July 18, 2016 (Issue: 1499)
The FDA has approved Onzetra Xsail (Avanir), a nasal powder formulation of sumatriptan, for acute treatment of migraine in adults. Nasal spray formulations of sumatriptan (Imitrex) and zolmitriptan (Zomig) have been available for many...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Onzetra Xsail - Sumatriptan Nasal Powder
Article code: 1499b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.